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COMPARISON OF TWO REDUCED INTENSITY ALLOGENEIC PERIPH-
ERAL BLOOD STEM TRANSPLANT CONDITIONING REGIMENS
Raﬂores, M.B., Rossetti, J.M., Shadduck, R.K., Lister, J. Western
Pennsylvania Hospital, Pittsburgh, PA.
We retrospectively compared treatment related mortality
(TRM), overall survival (OS), disease free survival (DFS) and
incidence of acute graft versus host disease (GVHD) of 2 reduced
intensity conditioning regimens (RICR) for sibling allogeneic pe-
ripheral blood stem cell transplantation in patients with poor risk
hematological malignancy. The original RICR, regimen A, con-
sisted of ﬂudarabine 30 mg/m2 (day 5 to day 2), melphalan
140-180 mg/m2 (day 3) and ethyol 910 mg/m2 (day 3) with
mycophenolate mofetil 1 g q12h and tacrolimus (serum level 5-15
ng/ml beginning day 3) as immunosuppressive therapy. Modiﬁ-
cations in regimen B included the use of a lower dose of melphalan
(100 mg/m2), and the addition of Thymoglobulin 2 mg/kg/d (day
2 to day 0). The method of Kaplan and Meier was used to
compare OS and DFS with the log rank test. The cumulative inci-
dence of TRM and acute GVHD in each group was compared using
the Pearson chi square method. Results: 25 patients were trans-
planted in A with median age of 47 years (range 19-65). 22 patients
were transplanted in B with median age of 44 years (range 18-68).
The cumulative incidence of grade 2-4 acute GVHD in patients
not receiving donor lymphocyte infusion (DLI) and alive for more
than 30 days post transplant was signiﬁcantly reduced in regimen B
(A 70%, B 6%; P .002). There was no signiﬁcant difference
at 1 year in OS (A  45%, B  40%; P  .70), DFS (P  .40) and
TRM (P  .40) between the two groups. Conclusion: Despite a
marked decrease in acute GVHD incidence with the addition of
Thymoglobulin and lowering of the melphalan dose in regimen B,
there was no decrease in TRM. Conversely, DFS was not worsened
by these changes suggesting no difference in efﬁcacy between the
two regimens. A decreased incidence of GVHD seems nonetheless
preferable and regimen B forms the basis for future investigation.
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UNRELATED CORD BLOOD TRANSPLANTATION—A SINGLE COLOM-
BIAN HOSPITAL EXPERIENCE
Cue´llar-Ambrosi, F.1,2, Quevedo-Ve´lez, A.1,2, Duque-Martelo, J.I.1,
Cuervo-Sierra, J.1, Sarmiento-Maldonado, M.1,2, Torres-Hernandez, J.D.1,2,
Vizcarra-Reyes, F.1,2, Vela´squez-Lopera, M.1,3, Calle-Fernandez, S.1,
Garcı´a, L.F.3, Rubinstein, P.4 1. Unidad de Trasplantes de Sangre y
Me´dula Osea-Hospital San Vicente de Pau´l, Medellı´n, Colombia; 2.
Facultad de Medicina, Universidad de Antioquia, Medellı´n, Colombia; 3.
Grupo de Inmunologı´a Celular e Inmunogene´tica, Facultad de Medicina,
Universidad de Antioquia, Medellı´n, Colombia; 4. F.H. Allen Labora-
tory of Immunogenetics and National Cord Blood Program, New York
Blood Center, New York, NY.
In recent years, umbilical cord blood (UCB) has emerged as a
feasible alternative source of hematopoietic progenitors (CD34)
for allogeneic stem cell transplantation, mainly in patients who lack
HLA-matched related marrow donors. Since the ﬁrst unrelated
donor transplant in 1993 more than 3500 patients have received
unrelated UCB transplants for a variety of malignant and non-
malignant diseases. At the Hospital San Vicente de Pau´l in Medel-
lı´n,Colombia, 12 patients, 10 children and two adults have been
transplanted with unrelated UCB since 2001. 8 patients had no-
malignant bone marrow diseases and 4 had malignant diseases.
Median age was 9.5 years (1-28). Unrelated UCB units were
provided by The New York Blood Center. Nine cord units were
HLA-matched 4/6, two 5/6 and three 6/6. Two adults received
more than one unit. Conditioning regimens were non-myeloabla-
tive in 4 cases and in 8 busulfan-cyclophosphamide-ATG/ TBI-
cyclophosphamide-ﬂudarabine-ATG. The median cryopreserved
nucleated cell dose in children was 67.6  106 (35.7-165.7  106)
and in the adult patients 42.1  106 (30-54.1  106). Engraftment
occurred in 7/10 of the assessable cases (70%). Median time of
neutrophil and platelet recovery (ANC 	500/dl and PTL
	20000/dl untransfused) was 24 days (19-34) and 35 days (28-58)
respectively. Of the recipients who engrafted, 2/7 (28%) patients
developed aGvHD grade 0-II and one (14%) grade III-IV. One of
these patients had limited cGvHD. Full chimerism was detected in all
alive patients day 100 but one who had acquired aplastic anemia
with initial autologous recovery and late relapse. Median follow-up
time was 22 months (6-54 months). 5/12 (42%) of patients are alive
and in good conditions. Treatment related mortality occurred in 4/12
(30%) of the cases, 2 patients died due to relapse and one of dissem-
inated M. bovis BCG infection on day 243. Although limited, this
experience is encouraging and demonstrates that UCB transplanta-
tion is feasible in developing countries such as Colombia and corre-
lated with the previously reported data.
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POST-ENGRAFTMENT INFECTIONS IN ADULT PATIENTS TRANS-
PLANTED WITH SINGLE CORD BLOOD UNITS SUPPORTED BY CO-
INFUSION OF MOBILIZED PURIFIED HEMATOPOIETIC STEM CELLS
FROM A THIRD PARTY DONOR
Cabrera, R., Krsnik, I., Fore´s, R., Ruiz, E., Bautista, G., Navarro, B.,
Gayoso, J., Gil, S., Regidor, C., Sanjuan, I., Ojeda, E.,
Garcı´a-Marco, J.A., Ferna´ndez, M.N. Hematology, Hospital Puerta de
Hierro UAM, Madrid, Spain.
We have co-infused mobilized puriﬁed hematopoietic stem cells
from a third party donor to shorten neutropenia in single unit cord
blood transplantation (CBT). We describe post-engraftment in-
fections in 33 adults (22 male, median age 30, range 16-59) with
high-risk hematological diseases. Pre-CBT serology was: toxo-
plasma 12 positive/13 negative (4 received HSC from a seroposi-
tive donor)/8 unknown; 30 were positive for CMV. Seven patients
were HBsAb(), HBsAg() and 1 HBsAg() HBsAb(). ANC
	500/L was achieved by 32/33, median time 10 days (9-36) and
full CB chimerism by 32/33 cases. Most signiﬁcant infections
occurred after ANC recovery. There were 34 episodes of CMV
reactivation (3 deaths day 60 of CMV pneumonitis). Of 3
patients with CNS toxoplasmosis (2 sero pre-CBT), 1 died as a
result (day 70), 1 of acute GVHD (120) and 1 is alive on
Fansidar (570). One patient had visceral leishmaniasis (day180)
(BM aspirate for FUO; alive on amphotericin, day 410).Seven
patients developed hemorrhagic cystitis, 6 related to polyomavirus
(PCR on urine): 4 resolved with no treatment, 2 with cidofovir or
leﬂunomide, one had asymptomatic viruria. HBsAg reappeared in
3/7 HbsAb() HBsAg() patients (1 asymptomatic, 1 acute hep-
atitis and 1 cirrhosis). A HBsAg() patient was uneventfully trans-
planted on adefovir. Eight late (	120) episodes of HZV were
seen. A 27-year-old Spaniard died (day 39) of trypanosomiasis (BM
aspirate for FUO, positive PCR). Activation of pre-CBT transfusion-
related infection is suspected. CBT recipients suffer a high number of
non-bacterial post-engraftment infections, which seem related to de-
layed recovery of cell-mediated immunity. CMV heads the list but
early diagnostic techniques and antivirals are available. Our toxo-
plasma cases have prompted us to use prophylaxis in seropositive
patients. HBV reactivation among HBsAb() HBsAg() patients
raises the issue of prophylaxis during CBT versus serological moni-
toring and pre-emptive therapy. Leishmaniasis is endemic among our
dogs, so we search for it in FUO (BM examination and culture).
Polyomavirus viruria (50% of BMT recipients) precedes symptoms
but the value of prospective monitoring and antivirals is unknown.
CBT infections require wide pre-BMT screening, close analytical and
clinical monitoring, prophylactic/preemptive strategies or early ag-
gressive therapy and innovative immunotherapeutic approaches.
Grants PI04/2794 Allostem.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PA-
TIENTS OVER 50: THE SINGLE CENTRE EXPERIENCE
Cetkovsky, P., Vitek, A., Pohlreich, D., Zajickova, M., Markova, M.,
Valkova, V., Cermak, J., Maaloufova, J., Kouba, M., Soukup, P.,
Klener, P. Institute of Hematology and Blood Transfusion, Prague, Czech
Republic.
Introduction: Hematopoietic stem cell transplantation (HSCT)
is an effective treatment modality, but it is associated with signif-
icant morbidity and mortality, especially in older patients (pts)
following myeloablative regimens (MY). For this reason an age
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